The committee responsible for recommending national health screening programs in the UK has faced significant backlash for its decision not to implement a widespread prostate cancer screening program. Critics argue that the committee's composition, notably the lack of urologists, undermines its ability to make informed decisions on a disease that is the most common cancer in the UK.
Professor Sir Mike Richards, chairman of the UK National Screening Committee (UKNSC), revealed his own experience with prostate cancer, having been diagnosed and treated after taking a PSA blood test. Despite his personal advocacy for awareness, the committee's final recommendation, released in May, proposes screening only for men aged 45 to 61 with a specific gene mutation and a family history of certain cancers, a criterion expected to invite as few as 1,500 individuals. This narrow scope has been branded a "profound disappointment" and a "real step back" by patient advocacy groups, who warn of avoidable deaths.
The UKNSC, an independent body overseen by the Department of Health and Social Care, makes recommendations to ministers and the NHS based on key principles. These include the existence of a reliable test, effective treatment, and evidence that screening offers "more benefit than harm at a reasonable cost." The committee has cited concerns that PSA tests can be unreliable and that many prostate cancers grow too slowly to cause problems, leading to unnecessary risks of impotence and incontinence from treatment.
However, a striking omission from the 13-member committee is any representation from urologists, the specialists who diagnose and treat prostate cancer. This lack of direct clinical expertise has been a major point of contention. Chris Booth, a retired consultant urologist and founder of men's health charity Chaps, called the committee's decision "incomprehensible" and warned it "will cost lives," asserting that PSA testing, combined with modern MRI scans, is a "cheap and effective" method for identifying men who require further investigation.
UKNSC director of programmes Professor Anne Mackie has consistently emphasized the potential harms of screening. In past public statements and blog posts, she has advocated for a cautious approach, suggesting that "all screening does some form of harm" and that "early detection is not always a good thing." She has stressed the importance of evidence demonstrating that screening benefits the population overall, rather than relying on individual clinician opinions or anecdotal evidence. Other committee members, such as clinical genetics consultant Anneke Lucassen and professor of public health Chris Hyde, have echoed this sentiment, emphasizing "prudence, not popularity" and the need to ensure benefits significantly outweigh harms.
Outside the committee, many experts hold a different view. The British Association of Urological Surgeons expressed disappointment, noting that the committee's recommendations apply to a "relatively small proportion of men at increased risk" and that identifying them presents significant practical challenges. David James of the Prostate Cancer Research charity accused the committee of being "static and backwards-looking," arguing that its evidence base predates significant advancements in diagnostic and management techniques.
Concerns have also been raised regarding the committee's diversity. Professor Frank Chinegwundoh, a consultant urologist, highlighted the disproportionate risk faced by black men, who are twice as likely to develop prostate cancer, and noted the absence of any black members on the committee. Oscar-winning director Sir Steve McQueen, whose father died of prostate cancer, branded the committee "indefensible" for not extending screening to black men and questioned the lack of diverse perspectives.
While the UKNSC maintains that widespread screening is not ruled out indefinitely and may change with new evidence, campaigners express concern that such a shift could be a lengthy process. The committee's history with lung cancer screening, where a recommendation was delayed by nearly a decade compared to its approval in the US, fuels these worries. Patient groups and many men over 50 hope for a more rapid reconsideration of its stance on prostate cancer screening.